| Autor: |
Lesch CA; Department of Immunopathology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, MI, USA., Kraus ER, Sanchez B, Gilbertsen R, Guglietta A |
| Jazyk: |
angličtina |
| Zdroj: |
Methods and findings in experimental and clinical pharmacology [Methods Find Exp Clin Pharmacol] 1999 Mar; Vol. 21 (2), pp. 99-104. |
| DOI: |
10.1358/mf.1999.21.2.529236 |
| Abstrakt: |
Expression of the COX-2 enzyme has been reported in animal models of inflammatory bowel disease (IBD) as well as in patients affected by ulcerative colitis and Crohn's disease. Recently, selective inhibitors of COX-2 have become available. In this study we have evaluated three highly selective COX-2 inhibitors, NS-398, SC-58125 and PD-138387, on the trinitro-benzene sulfonic acid (TNBS) model of colitis in rats. Daily oral administration of the three compounds evaluated up to a dose of 100 mg/kg failed to significantly modify any of the parameters evaluated. Our data show that despite their potent extraintestinal antiinflammatory activity, COX-2 inhibitors do not seem to have any beneficial effect in TNBS colitis and raise the question whether this therapeutic approach would be beneficial in patients with IBD. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
